November 10, 2019 at 2:57 pm

Gabelli Funds LLC Buys Shares of 110,850 Personalis (NASDAQ:PSNL)

by

Gabelli Funds LLC bought a new stake in Personalis (NASDAQ:PSNL) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 110,850 shares of the company’s stock, valued at approximately $1,627,000.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Other large investors have also recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in Personalis in the 2nd quarter valued at about $228,000. Wellington Shields & Co. LLC acquired a new position in Personalis in the 2nd quarter valued at about $1,765,000. Board of Trustees of The Leland Stanford Junior University acquired a new position in Personalis in the 2nd quarter valued at about $38,749,000. Janus Henderson Group PLC acquired a new position in Personalis in the 2nd quarter valued at about $13,554,000. Finally, Farallon Capital Management LLC acquired a new position in Personalis in the 2nd quarter valued at about $5,021,000. Institutional investors own 50.35% of the company’s stock.

Shares of PSNL stock traded up $0.29 during trading hours on Friday, hitting $10.46. The company had a trading volume of 185,500 shares, compared to its average volume of 355,310. Personalis has a fifty-two week low of $9.65 and a fifty-two week high of $31.88. The business’s fifty day moving average is $12.46. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.06 and a current ratio of 3.13.

Personalis (NASDAQ:PSNL) last posted its earnings results on Tuesday, August 13th. The company reported ($0.89) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.58). The company had revenue of $15.80 million for the quarter, compared to analysts’ expectations of $14.92 million. The company’s quarterly revenue was up 79.5% compared to the same quarter last year. As a group, research analysts predict that Personalis will post -0.92 EPS for the current fiscal year.

Several equities analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Personalis from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Wednesday, October 23rd. Oppenheimer assumed coverage on shares of Personalis in a report on Monday, July 15th. They issued an “outperform” rating and a $29.00 price objective on the stock. CIBC assumed coverage on shares of Personalis in a report on Monday, July 15th. They issued an “outperform” rating and a $29.00 price objective on the stock. Cowen assumed coverage on shares of Personalis in a report on Monday, July 15th. They issued an “outperform” rating on the stock. Finally, Bank of America upgraded shares of Personalis from a “neutral” rating to a “buy” rating and set a $22.00 price objective on the stock in a report on Thursday, September 26th. Six research analysts have rated the stock with a buy rating, Personalis currently has an average rating of “Buy” and a consensus price target of $24.20.

About Personalis

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.

Featured Article: Should I follow buy, hold and sell recommendations?

Want to see what other hedge funds are holding PSNL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Personalis (NASDAQ:PSNL).

Institutional Ownership by Quarter for Personalis (NASDAQ:PSNL)

Leave a Comment

Your email address will not be published. Required fields are marked *